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against inﬂuenzaA(H7N9)were testedwith
inﬂuenza Avirus subtype H7N1 antigen to
ﬁnd out its relatedness by means of the HI
assay. The H7 antigen reacted with WHO
reference antibodies to high titers (HI titer,
320), indicating antigenic similarity with
inﬂuenza A(H7N9) isolated from China.
This revealed the appropriateness of
using the H7 virus antigen in the study.
All serum samples from the high-risk
group and the general population were
negative for antibodies against inﬂuenza
A(H7) strains and inﬂuenza A(H5N1).
This indicated that there is no popula-
tion-immunity against inﬂuenza A(H7)
and inﬂuenza A(H5N1), and these virus-
es did not cause human infections in the
study population. Sera from the general
population were also negative for anti-
bodies against H9N2 virus. Isolation of
inﬂuenza A(H9N2) has been reported
among poultry from India [6]. It has
been shown that 4.7% and 3.8% of poul-
try workers from Pune were positive by
the HI and MN assays, respectively, for
antibodies against inﬂuenza A(H9N2)
[7]. Of the serum samples from high-
risk groups in Jamshedpur, 10% (13/
128) and 5% (6/128) were positive by
the HI and MN assays, respectively, for
antibodies against inﬂuenza A(H9N2).
This could be due to circulation of
inﬂuenza A(H9N2), in poultry in Jam-
shedpur. This difference in seropreva-
lence of antibodies against inﬂuenza
A(H9N2) in Pune and Jamshedpur
could be due to differential environmen-
tal exposures. The seropositivity against
A(H9N2) virus was similar (P > 0.05) in
15–44 and ≥45 years age-groups. The
presence of antibodies against inﬂuenza
A(H9N2) in poultry workers suggests
possible transmission of avian inﬂuenza
viruses from poultry to humans. The pre-
sent study showed that antibody levels
against inﬂuenza A(H9N2) were higher
than those against other avian inﬂuenza
viruses, which is in agreement with ﬁnd-
ings reported by Boni et al. The limitation
of this study is that generalization is not
possible from the small number of sam-
ples studied.
In summary, animal-human interface
studies, together with enhanced clinical and
virologic surveillance in high-risk groups,
are required to track possible species trans-
fer of novel avian inﬂuenza viruses.
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Reply to Pawar et al
TO THE EDITOR—In this issue of the Jour-
nal and in a recent study, Pawar et al
reported results of serologic tests per-
formed on a high-risk group of 446 poul-
try workers and 162 individuals from the
general population in Maharashtra and
Jamshedpur states, India [1, 2]. None of
the 608 samples tested positive for anti-
bodies to inﬂuenza A virus subtypes H5N1
or H7N1 by hemagglutination-inhibition
(HI) or microneutralization (MN) assays.
None of the 162 individuals from the gene-
ral population tested positive for H9N2 an-
tibodies by HI or MN assay. A total of 4.7%
and 10% of high-risk individuals in Pune
and Jamshedpur, respectively, tested posi-
tive by the HI assay for inﬂuenza A(H9N2);
3.8% and 4.7%, respectively, had positive
results of the MN assay. The authors sug-
gest that this higher rate of seropositivity
could be related to the circulation of inﬂu-
enza A(H9N2) in Jamshedpur in poultry,
with resultant zoonotic spread to humans,
and reference our publication showing
presence of antibodies to avian inﬂuenza
virus antigens in Vietnam.
As noted by the authors, H9 titers were
highest among all antibodies to avian in-
ﬂuenza virus strains in our general popu-
lation sample [3]. Other publications
looking at high-risk individuals in South
East Asia have demonstrated a higher se-
ropositivity rate for inﬂuenza A(H9)
strains, compared with inﬂuenza A(H5)
and/or A(H7) strains [4–6], but this is
not a consistent ﬁnding globally, even in
high-risk groups [7, 8]. Vaccine studies
conducted in locations thought to have
a low risk of avian inﬂuenza exposure
(ie, the United Kingdom and United
States) found that up to a third of
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participants were seropositive for H9 [9–
11]. Of those positive for H9 antibodies
(>1:40 by the HI assay), a greater propor-
tion were born before 1968, and it was
postulated that this was related to cross-
reactivity from inﬂuenza A virus subtype
H2N2, which was circulating in humans
from 1957 to 1968. Within our data set,
there was a signiﬁcantly higher sero-
positivity (and, accordingly, mean titer)
for all avian strains in individuals born
before 1968 (multivariate analysis of var-
iance [MANOVA]: F = 4.7, P < .0005,
Pillai 0.1256), with the H9 titer being the
highest. However, when we investigate
other birth year cutoffs (±20 years), we
ﬁnd the same trend, suggesting that this
effect is more related to an increase in age
rather than to a speciﬁc exposure event.
In the Vietnam sample set (n = 1424;
slightly reduced due to quality checks
from our original sample set), antibody
titers to avian inﬂuenza A virus antigens
increased with age. The optimal ﬁtted re-
gression curve among nonlinear models
was a ﬁfth-order polynomial (ANOVA:
P < .001), but this curve provided no ad-
ditional qualitative explanations of the
data than the second best ﬁt model, a
simple quadratic regression (Figure 1).
Titers to H9 antigen increase more rapid-
ly with age than titers to H7 or H5. One
hypothesis is that this difference is caused
by varying levels of exposure to avian in-
ﬂuenza viruses. A second hypothesis is
that this is caused by differences in
cross-reactivity between human inﬂuenza
antibodies and each of the subtypes H9,
H7, and H5. Our analysis provides more
support for the second hypothesis (sup-
plementary ﬁgures 1 and 2 in the article
by Boni et al [3]).
As noted in our article, the microarray
assay used in this analysis is more sensi-
tive than traditional HI and MN tests
when comparing titers for the homolo-
gous antigens. A problem in doing stud-
ies to evaluate zoonotic exposure is that
the exact antigenic composition of the in-
fecting virus may be unknown. Therefore,
HI/MN tests may yield false-negative re-
sults, a problem that is less evident with
the microarray, which measures anti-
bodies to the head of hemagglutinin and
is, therefore, more broadly reactive within
subtype. The differences we see in re-
sponse between H9 and H5 avian strains
(and to a lesser extent between H7 andH5
strains) are robust even when a much
higher titer cutoff is used (up to 1:320,
using microarray). With a cutoff titer of
1:20, 76% of individuals aged ≥50 years
test positive for H9 antibodies (compared
with 33% aged <50 years; χ2 = 89.9;
P < .001). With a more conservative (and
probably more appropriate) titer cutoff of
1:80, this percentage is 41% (18% among
those aged <50 years; χ2 = 40.6; P < .001),
suggesting that age distribution needs to
be carefully taken into account when de-
signing seroepidemiologic studies of avian
inﬂuenza virus in humans. This result is
robust for site effects in Vietnam, strength-
ening the hypothesis that this phenome-
non is not related to poultry exposure.
Understanding the best way to interpret
avian inﬂuenza virus serologic data,
including cross-reactions generated by
nonavian strains, is crucial for measuring
incidence in both high-risk groups and the
general population. The results generated
by Pawar et al contribute to this under-
standing, but their study, as with all studies
showing H9 positivity, should be inter-
preted with caution, as these H9-positive
signals are possibly cross-reactions.
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Figure 1. Scatterplot of avian strain titer against age with polynomial regressions lines. The black line denotes the second-order polynomial, and the red
line denotes the ﬁfth-order polynomial.
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Endothelial Activation and
Dysfunction in the
Pathogenesis of
Microvascular Obstruction in
Severe Malaria—AViable
Target for Therapeutic
Adjunctive Intervention
TO THE EDITOR—We read with interest
the recent review by White et al [1].
While we agree with the authors’ asser-
tion that microvascular obstruction
plays a fundamental role in the pathogen-
esis of lethal falciparum malaria [1], we
would like to express a contrasting opin-
ion on the potential impact of innovative
adjunctive treatment strategies for severe
(and cerebral) malaria.
White et al contend that “malaria re-
searchers have often been distracted by
epiphenomena,” (p. 193) prompting mis-
guided trials of adjunctive therapeutic
strategies in individuals with severe fal-
ciparum malaria [1]. Although the au-
thors acknowledge the critical role of
inﬂammation-induced endothelial acti-
vation in the binding of parasitized red
blood cells to vascular endothelium [1],
they neglect to discuss endothelial activa-
tion and dysfunction as viable targets
for development of novel adjunctive strat-
egies to improve clinical outcomes in life-
threatening malaria [2–4].
The angiopoietin-1/2 (Ang-1/2) and
Tie2 receptor system plays a key mecha-
nistic role in the regulation of endothelial
quiescence and activation. Notably, Ang-
1 levels are high and Ang-2 levels are low
in the peripheral blood of healthy indi-
viduals with quiescent endothelium. In
contrast, systemic inﬂammation causes
depressed Ang-1 levels and elevated
Ang-2 levels in serum/plasma, contribut-
ing to an activated and/or dysfunctional
endothelial state [4, 5]. Over the past dec-
ade, multiple groups have reported angio-
poietin-1/2 dysregulation (ie, low Ang-1/
high Ang-2) in the peripheral blood of
children and adults with severe and/or
cerebral malaria [6–11]. Furthermore, the
degree of dysregulation has been shown
to correlate with falciparum malaria dis-
ease severity and prognosis in multiple
populations [6–11]. These observations
strongly suggest that Ang-1/2 dysregula-
tion and associated endothelial activa-
tion/dysfunction are integral components
of the complex pathogenesis of severe
and cerebral malaria. Moreover, these ob-
servations are consistent with a growing
body of evidence supporting a central
role for endothelial dysfunction and Ang-
Tie2 dysregulation in the pathobiology
of other life-threatening infections, includ-
ing sepsis, multiple organ dysfunction
syndrome, acute respiratory distress syn-
drome, toxic shock syndrome, and hemo-
lytic-uremic syndrome [5, 12–17].
In conclusion, we contend that endo-
thelial activation/dysfunction represents
an attractive target for the development
of innovative adjunctive strategies to im-
prove clinical outcome in life-threatening
infections, including severe and cerebral
malaria. Potential interventions for inves-
tigation to decrease endothelial activation/
dysfunction and improve clinical outcome
in severe malaria include administration of
Ang-1 agonists, Ang-2 antagonists, Tie2
phosphatase inhibitors, recombinant
slit2N, sphingosine-1-phosphate agonists,
and nitric oxide [4, 6, 18–20].
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